edobacomab

Edobacomab, also known as Xomen-E5, is a murine monoclonal immunoglobulin M (IgM) antibody developed by Xoma Corporation for the treatment of serious Gram-negative infections and sepsis. It was specifically engineered to bind to the lipid A portion of bacterial endotoxin (lipopolysaccharide, or LPS), which is a highly conserved component across various Gram-negative bacteria and is responsible for triggering the systemic inflammatory response syndrome (SIRS) that leads to septic shock. By binding and neutralizing lipid A, edobacomab was intended to mitigate the toxic effects of endotoxemia. While early Phase II studies suggested potential benefits in reducing early morbidity and mortality, the drug failed to demonstrate a statistically significant survival benefit in larger, pivotal Phase III clinical trials. Consequently, its clinical development was discontinued.

Other names

anti-Lipid A murine monoclonal antibodyXomen E5